Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scancell HoldingsSCNLF 19 Days Sales Outstanding is 0.00 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 841 Biotechnology companies, Scancell Holdings ranks better than 70.39% on this metric.
Scancell Holdings (OTCPK:SCNLF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Scancell Holdings Days Sales Outstanding Related Terms
Scancell Holdings Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Scancell Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Days Sales Outstanding falls into.
Scancell Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a Days Sales Outstanding of 0.00 as of Oct. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Scancell Holdings and its competitors. Over the past decade, Scancell Holdings' Days Sales Outstanding has ranged from 44.20 to 44.80. According to the industry distribution chart, Scancell Holdings ranks #249 out of 841 companies in the Biotechnology industry, placing it in the top 29.6%.
Is Scancell Holdings' Days Sales Outstanding too high?
Scancell Holdings' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 44.20 to a high of 44.80. Based on the distribution chart, Scancell Holdings ranks #249 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #249 out of 841 companies for Days Sales Outstanding. This puts Scancell Holdings in the upper half of its industry. The industry median Days Sales Outstanding is 68.94. Historically, Scancell Holdings' own Days Sales Outstanding has ranged from 44.20 to 44.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Scancell Holdings' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Days Sales Outstanding is 0.00 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
19GF Score
Get the complete analysis for SCNLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
